FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386614978> ?p ?o ?g. }

• W4386614978 endingPage "1281" @default.
• W4386614978 startingPage "1272" @default.
• W4386614978 abstract "Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC).NAPOLI 3 was a randomised, open-label, phase 3 study conducted at 187 community and academic sites in 18 countries worldwide across Europe, North America, South America, Asia, and Australia. Patients with mPDAC and Eastern Cooperative Oncology Group performance status score 0 or 1 were randomly assigned (1:1) to receive NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous infusion over 46 h) on days 1 and 15 of a 28-day cycle or nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2, administered intravenously, on days 1, 8, and 15 of a 28-day cycle. Balanced block randomisation was stratified by geographical region, performance status, and liver metastases, managed through an interactive web response system. The primary endpoint was overall survival in the intention-to-treat population, evaluated when at least 543 events were observed across the two treatment groups. Safety was evaluated in all patients who received at least one dose of study treatment. This completed trial is registered with ClinicalTrials.gov, NCT04083235.Between Feb 19, 2020 and Aug 17, 2021, 770 patients were randomly assigned (NALIRIFOX, 383; nab-paclitaxel-gemcitabine, 387; median follow-up 16·1 months [IQR 13·4-19·1]). Median overall survival was 11·1 months (95% CI 10·0-12·1) with NALIRIFOX versus 9·2 months (8·3-10·6) with nab-paclitaxel-gemcitabine (hazard ratio 0·83; 95% CI 0·70-0·99; p=0·036). Grade 3 or higher treatment-emergent adverse events occurred in 322 (87%) of 370 patients receiving NALIRIFOX and 326 (86%) of 379 patients receiving nab-paclitaxel-gemcitabine; treatment-related deaths occurred in six (2%) patients in the NALIRIFOX group and eight (2%) patients in the nab-paclitaxel-gemcitabine group.Our findings support use of the NALIRIFOX regimen as a possible reference regimen for first-line treatment of mPDAC.Ipsen.For the plain language summary see Supplementary Materials section." @default.
• W4386614978 created "2023-09-12" @default.
• W4386614978 creator A5003957234 @default.
• W4386614978 creator A5012440329 @default.
• W4386614978 creator A5016800598 @default.
• W4386614978 creator A5017504528 @default.
• W4386614978 creator A5019473289 @default.
• W4386614978 creator A5021216873 @default.
• W4386614978 creator A5025015767 @default.
• W4386614978 creator A5049680516 @default.
• W4386614978 creator A5052709676 @default.
• W4386614978 creator A5057582488 @default.
• W4386614978 creator A5060536774 @default.
• W4386614978 creator A5071409429 @default.
• W4386614978 creator A5074891676 @default.
• W4386614978 creator A5075059160 @default.
• W4386614978 creator A5076298207 @default.
• W4386614978 creator A5082191671 @default.
• W4386614978 creator A5084349853 @default.
• W4386614978 creator A5088379063 @default.
• W4386614978 creator A5090645179 @default.
• W4386614978 date "2023-10-01" @default.
• W4386614978 modified "2023-10-14" @default.
• W4386614978 title "NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial" @default.
• W4386614978 cites W2019607817 @default.
• W4386614978 cites W2048816829 @default.
• W4386614978 cites W2066861571 @default.
• W4386614978 cites W2151253787 @default.
• W4386614978 cites W2165480504 @default.
• W4386614978 cites W2187917981 @default.
• W4386614978 cites W2210939121 @default.
• W4386614978 cites W2268755353 @default.
• W4386614978 cites W2790768119 @default.
• W4386614978 cites W2917919815 @default.
• W4386614978 cites W2959096163 @default.
• W4386614978 cites W3036393903 @default.
• W4386614978 cites W3136534534 @default.
• W4386614978 cites W3157420478 @default.
• W4386614978 doi "https://doi.org/10.1016/s0140-6736(23)01366-1" @default.
• W4386614978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37708904" @default.
• W4386614978 hasPublicationYear "2023" @default.
• W4386614978 type Work @default.
• W4386614978 citedByCount "3" @default.
• W4386614978 countsByYear W43866149782023 @default.
• W4386614978 crossrefType "journal-article" @default.
• W4386614978 hasAuthorship W4386614978A5003957234 @default.
• W4386614978 hasAuthorship W4386614978A5012440329 @default.
• W4386614978 hasAuthorship W4386614978A5016800598 @default.
• W4386614978 hasAuthorship W4386614978A5017504528 @default.
• W4386614978 hasAuthorship W4386614978A5019473289 @default.
• W4386614978 hasAuthorship W4386614978A5021216873 @default.
• W4386614978 hasAuthorship W4386614978A5025015767 @default.
• W4386614978 hasAuthorship W4386614978A5049680516 @default.
• W4386614978 hasAuthorship W4386614978A5052709676 @default.
• W4386614978 hasAuthorship W4386614978A5057582488 @default.
• W4386614978 hasAuthorship W4386614978A5060536774 @default.
• W4386614978 hasAuthorship W4386614978A5071409429 @default.
• W4386614978 hasAuthorship W4386614978A5074891676 @default.
• W4386614978 hasAuthorship W4386614978A5075059160 @default.
• W4386614978 hasAuthorship W4386614978A5076298207 @default.
• W4386614978 hasAuthorship W4386614978A5082191671 @default.
• W4386614978 hasAuthorship W4386614978A5084349853 @default.
• W4386614978 hasAuthorship W4386614978A5088379063 @default.
• W4386614978 hasAuthorship W4386614978A5090645179 @default.
• W4386614978 hasBestOaLocation W43866149781 @default.
• W4386614978 hasConcept C121608353 @default.
• W4386614978 hasConcept C126322002 @default.
• W4386614978 hasConcept C143998085 @default.
• W4386614978 hasConcept C168563851 @default.
• W4386614978 hasConcept C203092338 @default.
• W4386614978 hasConcept C2776694085 @default.
• W4386614978 hasConcept C2780258809 @default.
• W4386614978 hasConcept C2780962732 @default.
• W4386614978 hasConcept C2908647359 @default.
• W4386614978 hasConcept C526805850 @default.
• W4386614978 hasConcept C71924100 @default.
• W4386614978 hasConcept C99454951 @default.
• W4386614978 hasConceptScore W4386614978C121608353 @default.
• W4386614978 hasConceptScore W4386614978C126322002 @default.
• W4386614978 hasConceptScore W4386614978C143998085 @default.
• W4386614978 hasConceptScore W4386614978C168563851 @default.
• W4386614978 hasConceptScore W4386614978C203092338 @default.
• W4386614978 hasConceptScore W4386614978C2776694085 @default.
• W4386614978 hasConceptScore W4386614978C2780258809 @default.
• W4386614978 hasConceptScore W4386614978C2780962732 @default.
• W4386614978 hasConceptScore W4386614978C2908647359 @default.
• W4386614978 hasConceptScore W4386614978C526805850 @default.
• W4386614978 hasConceptScore W4386614978C71924100 @default.
• W4386614978 hasConceptScore W4386614978C99454951 @default.
• W4386614978 hasFunder F4320314481 @default.
• W4386614978 hasIssue "10409" @default.
• W4386614978 hasLocation W43866149781 @default.
• W4386614978 hasLocation W43866149782 @default.
• W4386614978 hasOpenAccess W4386614978 @default.
• W4386614978 hasPrimaryLocation W43866149781 @default.
• W4386614978 hasRelatedWork W2004787353 @default.
• W4386614978 hasRelatedWork W2016785168 @default.
• W4386614978 hasRelatedWork W2028640470 @default.

• next